Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients.
A retrospective review of AIDS-related oesophageal candidiasis was undertaken to identify clinical features helpful in predicting response to azole therapy and patient survival. Patients who had received daily azole prophylaxis against candidiasis were significantly less likely to respond to azole therapy than those who had not (P < 0.001). Patients who had lost > 5% of their body weight in the 2 months before oesophageal candidiasis were less likely to respond to azoles than the others (P < 0.001). Amongst those who had not received daily azoles, patients with a CD4+ cell count < 25/mm3 were less likely to respond to azole treatment (P = 0.05). The median survival beyond oesophageal candidiasis was 18 months. Survival from oesophageal candidiasis was significantly poorer for patients who did not respond to azole therapy but AIDS survival did not differ between azole responders and non-responders. Non-responders who had been taking daily azole prophylaxis had the poorest survival (median = 4 months).
Laing
R B
RB
Regional Infectious Disease Unit, City Hospital, Edinburgh, UK.
Brettle
R P
RP
Leen
C L
CL
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D000935:Antifungal Agents / Q000627:therapeutic use*; D001835:Body Weight; D018791:CD4 Lymphocyte Count; D002177:Candidiasis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D004352:Drug Resistance, Microbial; D004935:Esophageal Diseases / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D017741:Survivors; D016896:Treatment Outcome
D000935:Antifungal Agents; D015725:Fluconazole; D007654:Ketoconazole